相关实验视频

Updated: Feb 27, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

辅助性意马替尼或在患有KIT Exon 9突变的胃肠道筋瘤患者中的观察

Andrea Napolitano¹, Heikki Joensuu², Sara Rothschild³

¹The Royal Marsden Hospital and The Institute for Cancer Research, London, United Kingdom.

|February 26, 2026

概括

在被切除的胃肠道 stromal 瘤 (GISTs) 携带 KIT exon 9 突变的患者中,辅助意马替尼布治疗与延迟复发和改善生存率有关. 这支持其在高风险的GIST中使用,需要进一步研究最佳剂量.

科学领域:

在瘤学瘤学.
胃肠病学胃肠病学
分子生物学分子生物学

背景情况:

具有KIT外体9突变的胃肠道 stromal 瘤 (GIST) 是一个独特的亚组,对标准剂量伊马替尼的敏感性较低.
在切除KIT外因子9突变GIST的患者中,辅助性意马替尼的疗效尚不清楚.
了解治疗效益对于优化这种特定GIST群体患者的治疗结果至关重要.

研究的目的:

评估辅助伊马替尼与无复发生存率 (RFS) 和整体生存率 (OS) 之间的关联.
为了评估切除的GISTs患者的结果,这些GISTs具有KIT外体9突变.
调查辅助性意马替尼在预防这种GIST亚型的复发和改善生存中的作用.

主要方法:

国际,多中心队列研究367名患有局部化,KIT外体9突变GIST的患者接受手术.
辅助性意马替尼的使用被建模为依赖时间的共变量;分析包括因果推断的重叠权重 (OW).
主要终点:RFS和OS,在整个队列和高风险子组 (mNIH标准) 中分析.

主要成果:

辅助性意马替尼与显著降低复发或死亡的早期风险 (HR,0.19) 和改善的生存状况 (HR,0.37) 相关.
这些好处在整个队列和高风险小组中被观察到,由OW模型和灵敏度分析证实.
在高风险患者中,在400 mg/d和800 mg/d的伊马替尼布剂量之间没有发现结果的显著差异.

结论:

辅助性意马替尼独立地与KIT外基因9突变的切除GIST的延迟复发和改善生存相关.
这些发现支持使用辅助性意马替尼,特别是在具有KIT外基因9突变的高风险GIST中.
需要进行进一步的前性研究,以确定这种患者群体的最佳伊马替尼布剂量和治疗持续时间.

更多相关视频

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...